KTKozue Takahashi

Kozue Takahashi

*This is an algorithmically generated author record based on publicly available information.

Kozue Takahashi has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Usefulness of Dynamic FDG PET/CT in Detecting Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma Using a Silicon Photomultiplier PET Scanner

    by Hiroki Maruyama, Kozue Sato, Kentaro Takanami, Hiroshi Watabe, Hirofumi Kawakami, Yusuke Taniyama, Kei Takase, Takashi Kamei

    Purpose: In patients with esophageal squamous cell carcinoma (ESCC), it can be challenging to distinguish whether mediastinal lymph nodes (LNs) with an increased 18F-fluorodeoxyglucose (FDG) uptake are metastatic LNs or inflammatory ones. The aim of this study was to verify the superiority of dynamic 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) over conventional static positron emission tomography (PET) for detecting LN metastases in patients with ESCC using a silicon photomultiplier (SiPM) PET scanner. Patients and Methods: This prospective single-center study included 18 patients with ESCC who underwent dynamic PET/CT using SiPM PET and subsequently underwent radical esophagectomy and lymphadenectomy. FDG kinetics in the LNs were analyzed through spectral analysis and Patlak plots to calculate influx rate constant (Ki) values, followed by a conventional static PET scan and maximum standardized uptake value (SUVmax) measurement. Pathological analysis was used to define LN metastasis, and a receiver operating characteristic curve analysis was used to determine the diagnostic cutoffs for Ki and SUVmax. Results: Among 47 LNs (11 metastatic and 36 nonmetastatic) analyzed, metastatic LNs exhibited significantly higher Ki and SUVmax values than those of nonmetastatic LNs. The sensitivity for LN metastasis was comparable between SUVmax and Ki (both 72.7%). Meanwhile, the specificity in LN metastasis of Ki was higher than that of SUVmax (94.4% vs. 80.1%), as was the overall diagnostic accuracy of Ki (89.4% vs. 78.8%). Conclusions: Dynamic FDG PET/CT using SiPM PET may enhance the diagnostic accuracy for LN metastases in ESCC, enabling appropriate treatment intervention and improved outcomes for patients with ESCC.


  • Open Access

    Safety and Effectiveness of LC16m8 for Pre-Exposure Prophylaxis against mpox in a High-Risk Population: An Open-Label Randomized Trial

    by Nobumasa Okumura, Eriko Morino, Hidetoshi Nomoto, Mashiho Yanagi, Kozue Takahashi, Haruka Iwasaki, Yukari Uemura, Yosuke Shimizu, Daisuke Mizushima, Kazuaki Fukushima, et al.

    Background: The incidence of mpox cases has surged outside endemic regions since May 2022. However, data regarding the safety and efficacy of the LC16m8 vaccine are limited. This study provided opportunities for LC16m8 pre-exposure prophylaxis to high-risk individuals and conducted a randomized controlled trial to assess the effectiveness of LC16m8 in mpox prevention. Methods: This multicenter, randomized, open-label trial enrolled men and women aged ≥18 with high mpox risk. Participants were randomly assigned 1:1 to early or late vaccination groups, receiving vaccinations approximately 70 days apart. Vaccine effectiveness (VE) against mpox development between early and late vaccinations was the primary endpoint. VE against severe mpox, symptoms, “take” incidence, and adverse events were secondary endpoints. Results: A total of 570 and 565 patients were assigned to the early and late vaccination groups, respectively, and 530 and 476 were vaccinated. The median age was 41 years; 99.7% were male, 89.7% were Japanese, and 34.4% had human immunodeficiency virus (HIV). No mpox cases occurred, precluding VE calculations. The take rate was 90.3% (HIV-infected) and 94.6% (uninfected). Adverse events were observed in 97.2% and 98.2% of patients with and without HIV, respectively. No fatal adverse events were observed. Serious adverse events (SAE) were observed in 0.6% (HIV-infected) and 0.5% (uninfected) of patients. One participant without HIV reported pulmonary embolism and deep vein thrombosis as causally undeniable SAE. Local skin reactions: 96.6% (HIV-infected) and 97.9% (uninfected); systemic reactions: 63.6% (HIV-infected) and 64.2% (uninfected). Conclusions: The effectiveness of LC16m8 in mpox remains inconclusive. However, its use in well-controlled HIV-infected and -uninfected individuals showed no significant safety concerns, suggesting the potential for targeted vaccination strategies in at-risk groups. (Japan Registry of Clinical Trials number, jRCT1031230137.)


  • Open Access

    Efficacy and Viral Dynamics of Tecovirimat in Patients with MPOX: A Multicenter Open-Label, Double-Arm Trial in Japan

    by Yutaro Akiyama, Shinichiro Morioka, Shinya Tsuzuki, Tomoki Yoshikawa, Masaya Yamato, Hideta Nakamura, Masayuki Shimojima, Mizue Takakusaki, Sho Saito, Kozue Takahashi, et al.

    Introduction: Tecovirimat’s application in treating mpox remains under-researched, leaving gaps in clinical and virological understanding. Methods: The Tecopox study, conducted in Japan, assessed the efficacy and safety of oral tecovirimat therapy in patients with smallpox or mpox. Patients with mpox enrolled between June 28, 2022, and April 30, 2023, were included. We gathered demographic and clinical details along with blood, urine, pharyngeal swab, and skin lesion samples for viral analysis. A multivariable Tobit regression model was employed to identify factors influencing prolonged viral detection. Results: Nineteen patients were allocated to the tecovirimat group. The median age was 38.5 years, and all were male. Ten patients (52.6%) were infected with the human immunodeficiency virus (HIV). Sixteen patients (84.2%) had severe disease. Nine of the 15 patients (60.0%) (four patients withdrew before day 14) had negative PCR results for skin lesion specimens 14 days after inclusion. The mortality rates on days 14 and 30 were 0% and 0%, respectively. No severe adverse events were reported. HIV status and the number of days from symptom onset to tecovirimat administration were associated with lower Ct values ( p = 0.027 and p < 0.001, respectively). The median number of days when PCR testing did not detect the mpox virus in each patient was 19.5 days. Conclusion: The results suggest that early tecovirimat administration might reduce viral shedding duration, thereby mitigating infection spread. Moreover, patients infected with HIV appeared to have prolonged viral shedding, increasing the transmission risk compared to those without HIV. Keypoints: The Tecopox study revealed that early tecovirimat administration might reduce viral shedding duration, thereby mitigating infection spread. Moreover, patients infected with HIV appeared to have prolonged viral shedding, increasing the transmission risk compared to those without HIV.


  • Open Access

    Post COVID-19 condition of the Omicron variant of SARS-CoV-2

    by Shinichiro Morioka, Shinya Tsuzuki, Michiyo Suzuki, Mari Terada, Masako Akashi, Yasuyo Osanai, Chika Kuge, Mio Sanada, Keiko Tanaka, Taketomo Maruki, et al.

    Background No epidemiological data on post coronavirus disease (COVID-19) condition due to Omicron variant has been reported yet. Methods This was as a single-center, cross-sectional study, that interviewed via telephone the patients who recovered from Omicron COVID-19 infection (Omicron group), and surveyed via self-reporting questionnaire those patients infected with other strains (control group). Data on patients’ characteristics, information regarding the acute-phase COVID-19, as well as presence and duration of COVID-19-related symptoms were obtained. Post COVID-19 condition in this study was defined as a symptom that lasted at least 2 months within 3 months since the onset of COVID-19. We investigated and compared the prevalence of post COVID-19 condition in both groups after performing propensity score matching. Results We conducted interviews for 53 out of 128 patients with Omicron, and obtained 502 responses in the control group. After matching, 18 patients each in Omicron and control group had improved covariate balance of the older adult, female sex, obese patients, and vaccination status. There were no significant differences in the prevalence of each post-acute COVID-19 symptoms between the two groups. The numbers of patients with at least one post-acute COVID-19 symptom in the Omicron and the control group were 1 (5.6%) and 10 (55.6%) (p=0.003), respectively. Conclusion The prevalence of post Omicron COVID-19 conditions was less than that of the other strains. Further research with more participants is needed to investigate the precise epidemiology of post COVID-19 condition of Omicron, and its impact on health-related quality of life and social productivity.


  • Open Access

    A potential preventive method for scar stenosis after esophageal endoscopic mucosal resection using human amniotic epithelial cells in a porcine model

    by Yuji Konno, Chiaki Sato, Kazuaki Tokodai, Masatoshi Saito, Tetsuro Hoshiai, Yusuke Taniyama, Hiroshi Okamoto, Toshiaki Fukutomi, Yohei Ozawa, Naoto Ujiie, et al.

    Objectives: The current methods employed for esophageal endoscopic mucosal resection (EMR) involve the risk of adverse postprocedural complications. Therefore, this study aimed to develop a new method to prevent stenosis following a resection procedure using human amniotic epithelial cells in a porcine model.Methods: With the consent of a woman who underwent a cesarean section, amniotic epithelial cells were isolated from the amniotic membrane of the delivered placenta. Six swine were used for this study. Under general anesthesia, four EMRs using cap‐fitted microscope ulcers were performed on each porcine esophagus. Of the four ulcers, the two on the oral side were treated by injecting human amniotic epithelial (AE group) cells, and the remaining two on the anal side were left untreated (control group). One week after the procedure, the swine were sacrificed, and the ulcers were evaluated. The epithelialization rate was calculated by dividing the length of the epithelialized portion of each section by the length of the ulcer, which was determined using an optical microscope. Moreover, the mucosal thickening in each section was measured in terms of diameter.Results: The epithelialization rate was significantly higher in the AE group than in the control group. Mucosal thickening was not significantly different between the groups.Conclusions: Transplanting amniotic epithelial cells into the ulcer promoted ulcer epithelialization. Amniotic epithelial cell transplantation is a potential method for the management of ulcer scar stenosis following esophageal endoscopic submucosal dissection.